In what could turn out to be its largest acquisition ever, generic drug giant Mylan on Wednesday went public with a bid for competing Ireland-based drugmaker Perrigo Co. in a deal valued at about $30 billion.
The proposal, offering $205 a share in an unspecified combination of cash and stock, was contained in a letter from Mylan chairman Robert Coury delivered to Perrigo CEO Joseph Papa on Monday. Mylan released the letter Wednesday morning.
Mr. Coury’s letter indicated that joining forces with Perrigo would nearly double Mylan’s revenue, which was $7.7 billion in 2014.
Perrigo, based in Dublin, issued a brief statement Wednesday afternoon acknowledging the “unsolicited” proposal, saying, “The board of Perrigo will meet to discuss the proposal and a further announcement will be made when appropriate.”
Full Content: The New York Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas